Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Status:
NOT_YET_RECRUITING
Trial end date:
2036-04-01
Target enrollment:
Participant gender:
Summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.